Meta-Analysis on the Relationship between HLA-DRB1 Gene Polymorphism and Cervical Cancer in Chinese Population

Lin-zhen Wei1,2, Hai-lin Wang1, Xin Liu3, Ya-peng Lu2, Fei Xu2, Jin-qiu Yuan4, Ya-qin Ling3

1 Department of Obstetrics and Gynecology, Gansu Provincial Hospital, Lanzhou, Gansu, China, 2 The First Clinical Medicine College of Lanzhou University, Lanzhou, Gansu, China, 3 Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China, 4 Division of Epidemiology, School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong

Abstract

**Aim:** To determine the association between HLA-DRB1 haplotypes and risk of cervical cancer in unselected and samples from Chinese ethnicities.

**Methods:** A comprehensive search for articles from their inception to April 1st, 2013 was conducted from PubMed, Medline, Elsevier Science, Springer Link, Cochrane Library database, China biology medical literature database (CBM), China National Knowledge Infrastructure (CNKI), VIP, and Chinese literature database (Wang fang). A total of 1596 patients with cervical cancer and 2048 controls from the 12 studies on the relationship between gene polymorphism of HLA-DRB I and cervical cancer were performed and data were analyzed and processed using Review Manager 5.0 and Stata 11.0.

**Results:** Among the 13 family alleles, two (DRB1*03 and DRB1*08) were found to be negatively associated with cervical cancer in all studies or in Uighur subgroups, and two (DRB1*10 and DRB1*15) were positively associated with in all studies or in Uighur subgroups. Among the 25 specific alleles, six (DRB1*0301, *0403, *0404, *0803, *1312 and *1502) were associated with an increased risk cervical cancer in all studies. No significant association was established for other HLA-DRB1 family alleles and specific alleles. Ethnicity partially explained the race influence of DRB1*12, DRB1*14, DRB1*0301, DRB1*0403, DRB1*0404, DRB1*0803, DRB1*1312 and DRB1*1502 phenotypes.

**Conclusion:** Our results support the hypothesis that the HLA-DRB1 family alleles and specific alleles might influence the susceptibility or resistance to cervical cancer, suggesting that immune regulation may play a key role in this disease, although further investigations are still needed.

Introduction

Cervical cancer is one of the leading causes of cancer-related death among women worldwide, with 88% of cases occurring in less developed countries [1]. It is a grave health problem in China, with 132,300 women developing the disease each year, and is the second cancer in Chinese women [2]. Whereas a number of factors have been implicated in the etiology of cervical cancer, there is ample epidemiological and clinical evidence supporting that persistent infection with oncogenic types of human papillomavirus (HPV) predisposes to the disease, with the contribution of additional co-factors such as smoking and oral contraceptive use. A strong association exists between persistent HPV infections and risk of cervical lesions, especially for HPV types 16 and 18 [3]. Intriguingly, HPV infection is necessary but not sufficient to induce cellular abnormalities and the development of invasive cancer, since prospective studies consistently show that only a small fraction of infected women do eventually develop the disease [4]. A comprehensive study indicated that HPV interacts with other cofactors, including HLA class II alleles [5], that influence the risk of HPV persistence and progression to cervical cancer.

Human leukocyte antigens (HLA) comprises a family of Class I and Class II genes within the major histocompatibility complex, which is located on the short arm of chromosome 6 (6p) in humans [6]. HLA Class II genes encoded by DR, DQ, and DP genes are expressed in immune cells and are of importance in the regulation of the immune response to foreign antigens and discrimination of self from non-self antigens [7,8]. They present antigenic peptides to specific T-cells to initiate a cell-mediated immune response to HPV infection.

The etiology of cervical cancers might be related to risk factors, and HLA-DRB1 gene polymorphism was initially proposed in the late 1990s and has created considerable interest [9]. Findings from published studies that have examined the association HLA-DRB1 alleles and the risk of cervical cancer have been inconsistent. Several studies have reported a positive relation between HLA-DRB1 alleles and cervical cancer, but findings in different ethnic...
Methods

1. Literature and Research Strategy

Studies published in English and Chinese were considered in this study. Studies in English were identified through PubMed, Medline, Elsevier Science, Springer Link and Cochrane Library database from their earliest available date to April 1st, 2013. Reports in Chinese were found through China National Knowledge Infrastructure (CNKI) (1979–April 1st, 2013), Database of Chinese Scientific and Technical Periodicals (VIP) (1989–April 1st, 2013), Chinese literature database (Wan fang) (1986–April 1st, 2013) and China biology medical literature database (CBM) (1970–April 1st, 2013). Key words (‘‘cervical cancer’’ OR ‘‘cervical carcinoma’’ OR ‘‘uterine cervical carcinoma’’) and (‘‘HLA-DRB1’’ or ‘‘human leukocyte antigen’’ or ‘‘HLA antigen’’) were used in combination to retrieve the relevant literatures in all these databases. Moreover, we reviewed the reference lists from retrieved articles to search for further relevant studies. This Meta-analysis was planned, conducted, and reported in accord with standards of quality for reporting meta-analyses [13].

2. Inclusion and Exclusion Criteria

The inclusion criteria were: (1) studies presented original data and the number of genotype of HLA-DRB1 in cases and controls; (2) the articles provided raw data including odds ratio (OR) with 95% confidence interval (CI) and respective variance, or the relevant information could be calculated; (3) analytical study (case-control study or cohort study) or experimental study; (4) the diagnosis of CC was based on at least one of the following criteria: typical histological characteristics or colposcopy biopsies.

The exclusion criteria were: (1) raw data not available for retrieval; (2) repetitive reports (If data were duplicated in more than 1 study, we included the study with the largest number of cases); (3) the study did not fit the diagnosis criteria.

The frequency of HLA-DRB1 alleles varies according to ethnic and racial background, with some alleles being extremely rare. Therefore, articles were not required to identify all alleles for inclusion.

3. Data Extraction

To decide inclusively or exclusively, articles were identified by two independent reviewers using a standardized data extraction form designed by our group. Data with discrepancies in identification were discussed. If consensus was not achieved, the decision was made by a third reviewer. The following data were extracted from each study: the first author’s name, publication year, area where the study was performed, study period, range of age, number of cases and controls, HLA-DRB1 type alleles, diagnostic method, control sample description (if there was more than one control group, we choose the healthy group as the control group in order to minimize the confounder). The main features of the trials included in the meta-analysis are shown in Table 1.

4. Statistical Analysis

(1) The pooled OR and 95% CI were determined by Z test with P<0.05 considered statistically significant; (2) Heterogeneity across studies was estimated using the Cochran’s Q statistic and I² test. Meta analysis was carried out by using random-effects or fixed effects model based on the pooled effect estimates in the presence (p≤0.1 or I²≥50%) or absence (p>0.1 or I²<50%) of heterogeneity [14]. (3) To assess the presence of publication bias statistically, Begg’s test and Egger’s regression test were preformed where there were three or more studies [15–16]. p<0.05 was considered representative of statistically significant publication bias. (4) In this meta-analysis, in order to better investigate possible reasons of between-study heterogeneity, Studies were categorized into subgroups based on ethnicity status.(5)All analyses were performed using Review Manager 5.0 and Stata 11.0. All the P values were two sided.

Results

1. Study Selection and Study Characteristics

After carefully reading each article, 12 studies were eligible for the meta-analysis (including 5 in English and 7 in Chinese). A flow diagram of the study selection process is shown in Figure 1. We identified a total of 841 potentially relevant articles to our search criteria, of which twelve studies examining the association between HLA alleles and cervical cancer are presented in Table 1. All the selected studies presented original data on independent samples. A total of 1596 patients with cervical cancer and 2048 controls were included from 12 studies. Five studies used PCR-sequence specific primer for HLA, while others used PCR- sequence-based typing or PCR-sequence specific oligonucleotide for HLA.

2. Meta-analysis Results

A summary of the meta-analysis findings between HLA-DRB1 genetic polymorphisms and susceptibility to cervical cancer worldwide was provided in Table 2. In total, only thirty-eight HLA-DRB1 alleles from these studies were included in the meta-analysis, and 15 specific alleles were excluded because each was identified in only one study. A total of 13 DRB1 allele families and 25 specific alleles were extracted from the studies to investigate their association with cervical cancer.

Three allele families (DRB1*10, *14, and *15) conferred a significantly increased risk and four allele family (DRB1*03, *08, and *12) conferred a significant protective effect for cervical cancer. Their combined OR value, 95% CI and respective variance, or the relevant information could be calculated; (3) analytical study (case-control study or cohort study) or experimental study; (4) the diagnosis of CC was based on at least one of the following criteria: typical histological characteristics or colposcopy biopsies.

The exclusion criteria were: (1) raw data not available for retrieval; (2) repetitive reports (If data were duplicated in more than 1 study, we included the study with the largest number of cases); (3) the study did not fit the diagnosis criteria.

The frequency of HLA-DRB1 alleles varies according to ethnic and racial background, with some alleles being extremely rare. Therefore, articles were not required to identify all alleles for inclusion.

3. Data Extraction

To decide inclusively or exclusively, articles were identified by two independent reviewers using a standardized data extraction form designed by our group. Data with discrepancies in identification were discussed. If consensus was not achieved, the decision was made by a third reviewer. The following data were extracted from each study: the first author’s name, publication year, area where the study was performed, study period, range of age, number of cases and controls, HLA-DRB1 type alleles, diagnostic method, control sample description (if there was more than one control group, we choose the healthy group as the control group in order to minimize the confounder). The main features of the trials included in the meta-analysis are shown in Table 1.

4. Statistical Analysis

(1) The pooled OR and 95% CI were determined by Z test with P<0.05 considered statistically significant; (2) Heterogeneity across studies was estimated using the Cochran’s Q statistic and I² test. Meta analysis was carried out by using random-effects or fixed effects model based on the pooled effect estimates in the presence (p≤0.1 or I²≥50%) or absence (p>0.1 or I²<50%) of heterogeneity [14]. (3) To assess the presence of publication bias statistically, Begg’s test and Egger’s regression test were preformed where there were three or more studies [15–16]. p<0.05 was considered representative of statistically significant publication bias. (4) In this meta-analysis, in order to better investigate possible reasons of between-study heterogeneity, Studies were categorized into subgroups based on ethnicity status.(5)All analyses were performed using Review Manager 5.0 and Stata 11.0. All the P values were two sided.

Results

1. Study Selection and Study Characteristics

After carefully reading each article, 12 studies were eligible for the meta-analysis (including 5 in English and 7 in Chinese). A flow diagram of the study selection process is shown in Figure 1. We identified a total of 841 potentially relevant articles to our search criteria, of which twelve studies examining the association between HLA alleles and cervical cancer are presented in Table 1. All the selected studies presented original data on independent samples. A total of 1596 patients with cervical cancer and 2048 controls were included from 12 studies. Five studies used PCR-sequence specific primer for HLA, while others used PCR- sequence-based typing or PCR-sequence specific oligonucleotide for HLA.

2. Meta-analysis Results

A summary of the meta-analysis findings between HLA-DRB1 genetic polymorphisms and susceptibility to cervical cancer worldwide was provided in Table 2. In total, only thirty-eight HLA-DRB1 alleles from these studies were included in the meta-analysis, and 15 specific alleles were excluded because each was identified in only one study. A total of 13 DRB1 allele families and 25 specific alleles were extracted from the studies to investigate their association with cervical cancer.

Three allele families (DRB1*10, *14, and *15) conferred a significantly increased risk and four allele family (DRB1*03, *08, and *12) conferred a significant protective effect for cervical cancer. Their combined OR value, 95% CI and respective variance, or the relevant information could be calculated; (3) analytical study (case-control study or cohort study) or experimental study; (4) the diagnosis of CC was based on at least one of the following criteria: typical histological characteristics or colposcopy biopsies.

The exclusion criteria were: (1) raw data not available for retrieval; (2) repetitive reports (If data were duplicated in more than 1 study, we included the study with the largest number of cases); (3) the study did not fit the diagnosis criteria.

The frequency of HLA-DRB1 alleles varies according to ethnic and racial background, with some alleles being extremely rare. Therefore, articles were not required to identify all alleles for inclusion.

3. Data Extraction

To decide inclusively or exclusively, articles were identified by two independent reviewers using a standardized data extraction form designed by our group. Data with discrepancies in identification were discussed. If consensus was not achieved, the decision was made by a third reviewer. The following data were extracted from each study: the first author’s name, publication year, area where the study was performed, study period, range of age, number of cases and controls, HLA-DRB1 type alleles, diagnostic method, control sample description (if there was more than one control group, we choose the healthy group as the control group in order to minimize the confounder). The main features of the trials included in the meta-analysis are shown in Table 1.
Table 1. Characteristics of studies included in the meta-analysis.

| Authors and year of publication | Area and Nation | Number of cases | Number of controls | Number of DRB1 alleles studied | Diagnostic method of CC | Detection Methods | Control Type |
|---------------------------------|-----------------|-----------------|-------------------|-------------------------------|-------------------------|------------------|-------------|
| Yuh-Cheng Yang et al. [17], 2006 | Taiwan ND       | 126 50.1±12.3 (25.2–89.6) | 289 40.1±4.8 (31.7–46.5) | 32 Pathology | PCR-SBT | Healthy |
| Du Yang et al. [18], 2004       | Liaoning ND     | 43 47 (25–76) | 58 44 (22–62) | 13 Pathology | PCR-SSP | Healthy |
| Guzalnur. Abliz et al. [19], 2008 | Xinjiang Uighur | 200 45.5(23–76) | 200 44.3(21–66) | 13 Pathology | PCR-SSO | Benign lesions |
| Paul K.S. Chan et al. [20], 2005 | Hong Kong       | 173 45.6(20–82) | 323 36.8(25–56) | 13 Colposcopy biopsies | PCR-SSO | Blood donors |
| Yangguifang et al. [21], 2009   | Tianjin ND      | 30 37 (ND)      | 66 ND(45–60)      | 13 Pathology | PCR-SBT | Uterine fibroids |
| Suqi et al. [22], 2009          | Xinjiang Uighur | 192 ND          | 203 ND            | 1 Pathology | PCR-SSP | NILM |
| Lu Ling et al. [23], 2008       | Xinjiang Uighur | 300 45.4(23–76) | 300 43.8(21–66) | 13 Pathology | PCR-SSO | NILM benign lesions |
| Li Hua et al. [24], 2010         | Xinjiang Uighur | 90 45.9(21–76) | 90 43.2(21–66) | 13 Pathology | PCR-SSO | NILM benign lesions |
| Mirjili Jilili et al. [25], 2009 | Xinjiang Uighur | 92 44.5(23–72) | 92 42.8(21–66) | 13 Pathology | PCR-SSO | NILM benign lesions |
| Huang Linshuang et al. [26], 2007 | Liaoning ND    | 53 ND           | 34 ND             | 6 Pathology | PCR-SSP | Uterine fibroids |
| Yuping Wu et al. [27], 2007     | Han             | 133 46.7±11.4   | 98 40.5±8.5      | 17 Pathology | PCR-SBT | Healthy |
| M Zhao et al. [28], 2012        | Mid-western China ND | 69 ND | 201 ND | 17 Pathology | PCR-SBT | Healthy |

ND, not described; PCR-SSO, PCR-sequence-specific oligonucleotides; PCR-SBT, PCR- sequence-based typing; PCR-SSP, PCR- sequence-specific primer; NILM-Negative for intraepithelial lesion or malignancy.
doi:10.1371/journal.pone.0088439.t001
risk. However, there are no specific alleles with a decreased risk (Table 2). We found that there was no significant difference between the control groups of the various studies for following alleles: DRB1*0101, DRB1*0401, DRB1*0403, DRB1*0404, DRB1*0701, DRB1*0803, DRB1*1001, DRB1*1104, DRB1*1301, DRB1*1312, DRB1*1404, DRB1*1407, DRB1*1502 (P > 0.1 and I² < 50%). However, there was a significant difference between different studies in control groups for alleles: DRB1*0301, DRB1*0406, DRB1*0802, DRB1*0901, DRB1*1104, DRB1*1201, DRB1*1202, DRB1*1302, DRB1*1401, DRB1*1405, DRB1*1501, DRB1*1602 (P ≤ 0.1 and I² > 50%). (Table 2). Begg's and Egger's tests showed that results no evidence of publication bias.

3. Subgroup Analysis

Since considerable diversity of ethnic groups existed among these studies, we performed further subgroup analysis based on ethnicity. Among studies in Uighur, two allele families (DRB1*04 and *08) were significantly associated with a decreased risk and two allele families (DRB1*10 and *15) were significantly associated with an increased risk for cervical cancer. Only DRB1*04 and DRB1*15 had heterogeneous (P ≤ 0.1 and I² > 50%), so a random effect was used. Begg's and Egger's tests revealed no significant publication bias for any of the allele families (Table 3).

Discussion

Genetic susceptibility to cervical cancer has been a research focus, and it has been discussed that the polymorphisms of a number of immune response associated genes, including HLA-DR loci, affects the susceptibility to and clearance of persistent HPV infection among different populations. HLA plays an essential role in the pathogenesis of HPV virus-associated cervical cancer; HLA-II genes are expressed as cell-surface glycoproteins that bind short peptide epitope to CD4+ T cells. HLA-DR, a subtype of HLA class II molecules, has a particular binding motif that dictates a specific range of peptides that can physically bind in a groove on the surface of the HLA molecule [29].

Cervical cancer is mostly a virus infected disease. However, the susceptibility of individuals with persistent infection to develop invasive cervical cancer, even with the same HPV exposure, is varied. Host-factors, including gene polymorphisms, might be used to interpret these differences at least in part. Since many studies have revealed the relationship between HLA-DRB1 gene polymorphism and cervical cancer in different populations, it is currently considered as a disease marker and contributes to the genetic risk.

However, recent studies on the association between HLA-DRB1 allele polymorphisms and cervical cancer have been inconclusive and controversial. Climent [12] reported that the DRB1*11 and DRB1*16 alleles might be risk factors for the occurrence of cervical cancer (OR = 2.89, OR = 1.74, respectively), DRB1*01, DRB1*04, DRB1*14, and DRB1*15 may be protective alleles (OR = 0.52, OR = 0.60, OR = 0.33 and 0.65, respectively). Yuh-Cheng Yang3 DRB1*0701 and *1407 tended to confer a risk of CSCC (OR = 2.89 and 11.55, respectively). On the other hand, DRB1*1202 and *1401 played a major protective role in patients with cervical cancer (OR = 0.64 and 0.45, respectively). Furthermore, DRB1*15 was associated with susceptibility to cervical cancer in Swedish [11] and British [10] women, although several other studies, among American [30], French [31], and northwest English [32] women did not find an association between DRB1*1501 and cervical cancer.

Meta-analysis is a powerful method to increase the sample size from individual studies to enhance the statistical power of the analysis, which may reduce the probability that random error of producing false-positive or false-negative associations [33]. A total of 12 studies, including 3,410 cervical cancer cases and 1,735 healthy controls, were evaluated in the current meta-analysis,
Table 2. Meta-analysis of associations between HLA-DRB1 alleles and cervical cancer.

| Alleles | No. of study | Case | Control | heterogeneity | P value | \( I^2 \) value (%) for heterogeneity test | Model | OR (95% CI) | P value | Z | P value for Egger’s (Begg’s) bias test |
|---------|-------------|------|---------|--------------|---------|------------------------------------------|-------|-------------|---------|----|-------------------------------|
| 01      | 8           | 84/1077 | 79/1389 | 0.16 | 34% | F | 1.04 (0.75–1.43) | 0.83 | 0.21 | 0.983 (0.711) |
| 03      | 7           | 172/1024 | 272/1352 | 0.27 | 21% | F | 0.74 (0.59–0.91) | 0.005 | 2.82 | 0.986 (1.000) |
| 04      | 7           | 215/967 | 30/1264 | 0.03 | 58% | R | 0.94 (0.67–1.31) | 0.72 | 0.36 | 0.582 (0.548) |
| 07      | 6           | 314/898 | 315/1063 | 0.48 | 0% | F | 1.08 (0.88–1.32) | 0.46 | 0.74 | 0.821 (1.070) |
| 08      | 7           | 87/967 | 183/1264 | 0.12 | 41% | F | 0.68 (0.52–0.90) | 0.006 | 2.73 | 0.655 (1.000) |
| 09      | 6           | 139/898 | 175/1063 | 0.73 | 0% | F | 1.10 (0.86–1.42) | 0.46 | 0.74 | 0.849 (1.000) |
| 10      | 6           | 43/898 | 22/1063 | 0.92 | 0% | F | 2.30 (1.37–3.86) | 0.002 | 3.14 | 0.278 (0.707) |
| 11      | 8           | 194/1020 | 268/1298 | 0.001 | 71% | R | 0.89 (0.58–1.37) | 0.60 | 0.52 | 0.136 (0.266) |
| 12      | 5           | 77/898 | 162/865 | 0.83 | 0% | F | 0.63 (0.46–0.87) | 0.005 | 2.78 | 0.484 (0.707) |
| 13      | 8           | 171/1020 | 207/1298 | 0.04 | 52% | R | 0.88 (0.70–1.11) | 0.28 | 1.09 | 0.490 (0.386) |
| 14      | 6           | 100/898 | 92/1063 | 0.53 | 0% | F | 1.39 (1.03–1.88) | 0.03 | 2.15 | 0.139 (0.133) |
| 15      | 10          | 362/1307 | 307/1298 | 0.0007 | 69% | R | 1.62 (1.36–1.93) | <0.0001 | 5.32 | 0.582 (0.474) |
| 16      | 5           | 17/898 | 47/1063 | 0.95 | 0% | F | 0.56 (0.32–1.00) | 0.05 | 1.97 | 0.254 (0.086) |
| 0101    | 3           | 6/225 | 15/393 | 0.64 | 0% | F | 1.03 (0.40–2.67) | 0.94 | 0.07 | 0.316 (0.296) |
| 0301    | 2           | 4/156 | 23/355 | 0.07 | 69% | R | 4.36 (1.15–16.48) | 0.03 | 2.17 | NA |
| 0401    | 2           | 4/156 | 3/355 | 0.28 | 16% | F | 3.05 (0.67–13.84) | 0.15 | 1.45 | NA |
| 0403    | 2           | 18/156 | 15/355 | 0.37 | 0% | F | 2.98 (1.47–6.04) | 0.002 | 3.04 | NA |
| 0404    | 2           | 9/156 | 4/355 | 0.85 | 0% | F | 5.06 (1.62–15.79) | 0.005 | 2.79 | NA |
| 0406    | 2           | 14/156 | 8/355 | 0.02 | 82% | R | 1.82 (0.05–72.72) | 0.75 | 0.32 | NA |
| 0701    | 3           | 18/225 | 39/556 | 0.28 | 22% | F | 1.14 (0.63–2.06) | 0.67 | 0.43 | 0.469 (0.296) |
| 0802    | 2           | 4/156 | 4/355 | 0.07 | 70% | R | 5.24 (3.08–8.91) | 0.70 | 0.38 | NA |
| 0803    | 2           | 51/156 | 31/355 | 0.31 | 2% | F | 5.27 (3.19–8.70) | <0.0001 | 6.48 | NA |
| 0901    | 4           | 121/278 | 151/590 | 0.0001 | 97% | R | 0.93 (0.008–10.48) | 0.05 | 0.06 | 0.159 (1.000) |
| 1001    | 4           | 26/278 | 19/590 | 0.13 | 47% | F | 1.83 (0.93–3.60) | 0.08 | 1.75 | 0.471 (0.734) |
| 1101    | 2           | 55/156 | 31/355 | 0.01 | 83% | R | 4.21 (1.03–17.25) | 0.05 | 2.00 | NA |
| 1104    | 2           | 1/156 | 1/355 | 0.33 | 0% | F | 2.23 (0.31–15.94) | 0.42 | 0.80 | NA |
| 1201    | 3           | 33/225 | 55/556 | 0.0001 | 93% | R | 1.48 (0.14–15.63) | 0.74 | 0.74 | 0.818 (1.000) |
| 1202    | 2           | 79/156 | 33/355 | 0.0001 | 95% | R | 2.11 (0.02–260.74) | 0.076 | 0.30 | NA |
| 1301    | 3           | 2/225 | 6/556 | 0.38 | 0% | F | 1.09 (0.27–4.32) | 0.91 | 0.12 | 0.537 (1.000) |
| 1302    | 2           | 15/156 | 10/355 | 0.01 | 84% | R | 1.50 (0.03–68.16) | 0.83 | 0.21 | NA |
| 1312    | 3           | 6/250 | 1/453 | 0.99 | 0% | F | 6.38 (1.28–31.69) | 0.02 | 2.26 | 0.503 (1.000) |
| 1401    | 2           | 22/156 | 7/355 | 0.04 | 75% | R | 5.11 (0.60–43.31) | 0.13 | 1.50 | NA |
| 1404    | 2           | 1/156 | 2/355 | 0.22 | 35% | F | 1.64 (0.11–25.51) | 0.72 | 0.35 | NA |
| 1405    | 4           | 16/319 | 20/654 | 0.007 | 75% | R | 1.15 (0.16–8.28) | 0.89 | 0.14 | 0.330 (1.000) |
### Table 2. Meta-analysis of relationship between HLA-DRB1 allele polymorphism and cervical cancer in the Chinese Uighur population.

| Alleles | No. of study | Case (No.) | Control (No.) | Heterogeneity P value | I² value (%) | For heterogeneity test | Model | OR(95% CI) | P value | Z | P value for Egger's (Begg's) bias test |
|---------|--------------|------------|---------------|-----------------------|--------------|-----------------------|-------|------------|---------|---|-------------------------------------|
| 1407    | 2            | 1/156      | 2/355         | 0.23                  | 30%          | F                     | 1.50  | 0.25−9.10 | 0.66    | 0.44 | NA                                  |
| 1501    | 2            | 53/156     | 37/355        | 0.003                 | 89%          | R                     | 2.90  | 0.51−16.43 | 0.23    | 1.20 | NA                                  |
| 1502    | 2            | 20/156     | 22/355        | 0.35                  | 0%           | F                     | 2.26  | 1.18−4.33 | 0.01    | 2.45 | NA                                  |
| 1602    | 2            | 26/156     | 11/355        | 0.14                  | 55%          | R                     | 4.12  | 0.71−24.49 | 0.11    | 1.58 | NA                                  |

Heterogeneity is present when p values less than 0.1 or I² values equal or more than 50%.

doi:10.1371/journal.pone.0088439.t002

### Table 2. Cont.

| Alleles | No. of study | Case (No.) | Control (No.) | Heterogeneity P value | I² value (%) | For heterogeneity test | Model | OR(95% CI) | P value | Z | P value for Egger's (Begg's) bias test |
|---------|--------------|------------|---------------|-----------------------|--------------|-----------------------|-------|------------|---------|---|-------------------------------------|
| 1503    | 2            | 15/156     | 10/355        | 0.51                  | 80%          | R                     | 1.99  | 0.48−8.95 | 0.02    | 3.24 | 0.744(1.000)                        |
| 1504    | 2            | 10/156     | 15/355        | 0.42                  | 90%          | R                     | 2.10  | 0.81−5.63 | 0.006   | 2.67 | 0.373(1.000)                        |
| 1603    | 2            | 21/156     | 9/355         | 0.57                  | 50%          | F                     | 1.65  | 0.86−3.16 | 0.12    | 1.17 | 0.166(1.000)                        |
| 1604    | 2            | 23/156     | 8/355         | 0.62                  | 0%           | F                     | 2.46  | 1.20−5.01 | 0.002   | 3.12 | 0.227(1.000)                        |

Heterogeneity is present when p values less than 0.1 or I² values equal or more than 50%.

F: Fixed effect model (Peto Mantel-Haenszel); R: Random effect model (Dersimonian-Laird).

doi:10.1371/journal.pone.0088439.t002

### Table 3. Meta-analysis of relationship between HLA-DRB1 allele polymorphism and cervical cancer in the Chinese Uighur population.

| Alleles | No. of study | Case (No.) | Control (No.) | Heterogeneity P value | I² value (%) | For heterogeneity test | Model | OR(95% CI) | P value | Z | P value for Egger's (Begg's) bias test |
|---------|--------------|------------|---------------|-----------------------|--------------|-----------------------|-------|------------|---------|---|-------------------------------------|
| 01      | 4            | 69/682     | 55/682        | 0.84                  | 0%           | F                     | 1.28  | 0.89−1.86 | 0.19    | 1.32 | 0.590(0.734)                        |
| 03      | 4            | 123/682    | 42/682        | 0.66                  | 0%           | F                     | 0.62  | 0.48−0.81 | 0.0004  | 3.57 | 0.970(1.000)                        |
| 04      | 4            | 142/682    | 170/682       | 0.04                  | 0%           | R                     | 0.79  | 0.50−1.24 | 0.30    | 1.04 | 0.744(1.000)                        |
| 07      | 4            | 294/682    | 273/682       | 0.70                  | 0%           | F                     | 1.14  | 0.92−1.41 | 0.25    | 1.15 | 0.297(0.089)                        |
| 08      | 4            | 42/682     | 76/682        | 0.75                  | 0%           | F                     | 0.52  | 0.35−0.77 | 0.001   | 3.24 | 0.696(1.000)                        |
| 09      | 4            | 73/682     | 71/682        | 0.58                  | 0%           | F                     | 1.03  | 0.73−1.46 | 0.86    | 0.18 | 0.621(0.737)                        |
| 10      | 4            | 33/682     | 15/682        | 0.83                  | 0%           | F                     | 2.22  | 1.21−4.10 | 0.01    | 2.56 | 0.159(0.308)                        |
| 11      | 4            | 139/682    | 199/682       | 0.01                  | 74%          | R                     | 0.63  | 0.37−1.06 | 0.08    | 0.75 | 0.993(0.734)                        |
| 12      | 4            | 32/682     | 43/682        | 1.00                  | 0%           | F                     | 0.73  | 0.42−1.27 | 0.26    | 1.12 | 0.662(0.734)                        |
| 13      | 4            | 112/682    | 126/682       | 1.00                  | 0%           | F                     | 0.87  | 0.66−1.15 | 0.32    | 1.00 | 0.063(0.089)                        |
| 14      | 4            | 71/682     | 50/682        | 0.93                  | 0%           | F                     | 1.47  | 1.01−2.15 | 0.05    | 1.99 | 0.895(0.734)                        |
| 15      | 5            | 247/874    | 162/885       | 0.08                  | 52%          | R                     | 1.77  | 1.26−2.50 | 0.001   | 3.29 | 0.800(0.806)                        |
| 16      | 4            | 5/682      | 8/682         | 0.94                  | 0%           | F                     | 0.62  | 0.20−1.91 | 0.41    | 0.83 | 0.001(0.296)                        |

F: Fixed effect model (Peto Mantel-Haenszel); R: Random effect model (Dersimonian-Laird).

doi:10.1371/journal.pone.0088439.t003
which addressed 38 HLA-DRB1 subtypes. The results showed that DRB1*03, *08,*11, and *16 were strongly related to cervical cancer as protective factors. Meanwhile, DRB1*10, *14,*15, *0301, *0403, *0404, *0803, *1312 and *1502 might be regarded as risk factors, but we could not gain significant results because *Q031, *Q043, *Q044 and *Q093 were only reported two papers—these results really require further studies. However, we could not find an association between special alleles with cervical cancer in Uighur population. Additionally, we found that DRB1*11, DRB1*0802 and DRB1*1405 in all groups and DRB1*11in subgroup have high heterogeneity but no evidence has shown the existence of publication bias.

A subgroup analysis was performed to evaluate the effects of ethnicity on the meta-analysis. When the six studies in Uighurs were analyzed separately (Table 3), 5 of 13 HLA-DRB1 allele families were found to be significantly associated with cervical cancer. Three allele families (DRB1*10, and *15) conferred susceptibility to cervical cancer and 2 allele families (DRB1*03 and *08) were protective. While such associations have previously been reported for DRB1*03, *08, *10 and *15, an association between HLA-DRB1*12, *14, and *16 alleles and cervical cancer in subgroup studies were inconsistent with previous one in all groups, which implies that some family alleles have a same effect between Uighur groups and other groups and some confer a genetic effect respective of ethnicity. One limitation for this meta-analysis is that not all alleles were reported in each Uighur study. Thus, one can not reach a conclusion that whether special alleles have a difference in the different groups through the meta-analysis.

Although the correlation of cervical cancer with HLA-DRB1 genes has been demonstrated by various studies, the mechanisms underlying the effect have yet to be elucidated. Human tumor cells express diverse types of antigens, depending on the etiology and pathogenesis of the disease [34]. Because tumor development is preceded by chronic inflammation, immune responses, whether towards the infectious agent itself or against tumor antigens, may be critical for development of tumor. HLA-DRB1 alleles may affect the way the human body involved in the immune system and in cell cycle [35]. Some alleles are considered protective while others increase the risk of developing a certain condition. Moreover, the same allele can be positively associated with a certain condition while it can be negatively associated with another.

This study also has its own limitations. First, since little literature including DRB1 genotype was available for inclusion in our meta-analysis, not all alleles were not reported in each Uighur study. This might not reach a conclusion that whether special alleles have a difference in the different groups. Since only published studies written in English and Chinese were included in the meta-analysis, publication bias may occur. Secondly, although people in control groups were mainly healthy adults, there may be specific genetic effects among these controls and we could not entirely rule out the possibility of the incidence of cervical cancer in the future. It is necessary to use standardized unbiased methods on homogeneous cervical cancer patients and well matched controls. Third, our results were based on unadjusted estimates. A more precise analysis should be conducted with individual data, which would allow the adjustment by other co-variates including age, ethnicity, family history, environmental factors and lifestyle. Finally, five studies used PCR-sequence specific primer for HLA, while others used PCR-sequence-based typing or PCR-sequence specific oligonucleotide for HLA at the time of the studies. The different typing methods were not identical between different laboratories, which might lead to a heterogeneity in current meta-analysis.

In summary, in the present study we performed a meta-analysis on the association of cervical cancer with the HLA-DRB1 alleles. Our results indicated the difference of HLA-DRB1 genetic susceptibility of cervical cancer in Chinese population. For the HLA-DRB1 family alleles polymorphism, a significantly association with cervical cancer was found in Chinese Uighur group, indicating that HLA-DRB1*03 and DRB1*08 alleles may be the protective factors for cervical cancer and HLA-DRB1*10 and DRB1*15 alleles may be the risk factors for cervical cancer, but not data found in other ethnic groups. Overall, ethnicity may play an key role in cervical cancer outcome. A major limitation of this pooled analysis of previously published data relies on the fact that several studies included limited sample size, so we can not get information of special alleles in Uighur group. More studies on individuals from various ethnic groups and large-scale and well designed case-control studies are needed to determine the role of HLA-DRB1 polymorphisms in the outcome of cervical cancer.

Supporting information

Checklist S1 PRISMA checklist.

(DOC)

Acknowledgments

We are greatly indebted to Professor Wu for his help in data supply.

Author Contributions

Conceived and designed the experiments: LZW HLIW. Performed the experiments: XL. Analyzed the data: YPL JQY. Contributed reagents/materials/analysis tools: YQL FX. Wrote the paper: LZW.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. International journal of cancer, 127,2893–2917.
2. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. International journal of cancer, 80,827–841.
3. Schlecht NF, Kulaug S, Robitaille J, Ferreira S, Santos M, et al. (2001) Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA: the journal of the American Medical Association, 286,3106–3114.
4. Ho GY, Burk RD, Klein S, Kadiash AS, Chang C, et al. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. Journal of the National Cancer Institute, 87,1365–1371.
5. Mahmod SM, Robinson K, Richardson H, Tellier PP, Ferencya AS, et al. (2007) HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. Journal of Infectious Diseases, 196,82–90.
6. Hilleshöm A, Wang SS (2002) Host and viral genetics and risk of cervical cancer: a review. Virus research, 89,229–240.
7. Klein J, Sato A (2000) The HLA system. First of two parts. The New England journal of medicine, 343,702–709.
8. Klein J, Sato A (2000) Advances in immunology: The HLA system. Second of two parts. The New England journal of medicine. 343,782–786.
9. Schreuder G, Hurley C, Marsh S, Lau M, Maires M, et al. (2001) The HLA dictionary 2001: a summary of HLA-A,-B,-C,-DRB1/3/4/5,-DQB1 alleles and their association with serologically defined HLA-A,B,-C,-DR,-and-DQ antigens Human immunology, 62,826–849.
10. Cuzick J, Terry G, Ho L, Monaghan J, Lopes A, et al. (2000) Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. British journal of cancer, 82,1348–1352.
11. Bokesov AR, Josefson AM, Gyllensten UB (2001) HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. International journal of cancer, 93,817–822.
12. Climent C, Nazario G, Umpierre S, Quintero M, Gorbea S (2007) Major histocompatibility complex class II polymorphisms and risk of cervical cancer in Puerto Rican women. Puerto Rico health sciences journal, 26,97–101.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology. JAMA: the journal of the American Medical Association, 283,2008–2012.
14. Higgins J, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21,1539–1558.
15. Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. Journal of epidemiology, 15,235–243.
16. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA: the journal of the American Medical Association, 295(6),676–80.
17. Yang YC, Chang TY, Lee YJ, Su TH, Dang CW, et al. (2006) HLA-DRB1 alleles and cervical squamous cell carcinoma: experimental study and meta-analysis. Human immunology, 67,331–340.
18. Du Y, Dong YZ, Wang HM, Li JP (2011) The relationship between human leukocyte antigen HLA-DRB1*15 allele and cervical cancer in Liaoning province women. Chinese and foreign women health, 6,063–064.
19. Guzalnur A, Lu L, Miriguli A, Fang X, Chen H (2008) The Relationship between Race and Susceptibility to Cervical Cancer in Xinjiang Uighur Women. Chinese journal of clinical oncology, 35,629–632.
20. Chan PK, Cheung TH, Lin CK, Liu SS, Yin SF, et al. (2007) Association Between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese. Journal of medical virology, 79,970–976.
21. Huang JS, Lin P, Qi Y, Zhou D, Zhang SL (2006) Study of HLA-DRB1 alleles and risk of cervical cancer. Chinese journal of obstetrics and gynecology, 41,715–716.
22. Wu Y, Liu B, Lin W, Xu Y, Li L, et al. (2007) Human leukocyte antigen class II alleles and risk of cervical cancer in China. Human immunology, 68,192–200.
23. Zhao M, Qiu L, Tao N, Zhang L, Wu X, et al. (2012) HLA DRB allele polymorphisms and risk of cervical cancer associated with human papillomavirus infection: a population study in China. European journal of gynaecological oncology, 34,54–59.
24. Godfinkin A, Davenport M, Hill AV (2005) Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology, 41,1383–1390.
25. Madeleine MM, Brumback B, Cushing-Haugen KL, Schwartz SM, Daling JR, et al. (2002) Human leukocyte antigen class II and cervical cancer risk: a population-based study. Journal of Infectious Diseases, 186,1565–1574.
26. Sastre-Garau X, Losse MN, Vincent-Salomon A, Favre M, Mouret E, et al. (1996) Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer, 69,159–164.
27. Duggan-Keen MF, Kretting P, Stevens F, Smit M, Sujides P, et al. (1996) Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. International Journal of Immunogenetics, 23,275–284.
28. Wang J, Pan HF, Hu YT, Zhu Y, He Q (2010) Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: a meta-analysis. Digestive diseases and sciences, 55,1028–1035.
29. Jager D, Jager E, Knuth A (2001) Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. Journal of clinical pathology, 54,669–674.
30. Castro FA, Haimala K, Sareneva I, Schmitt M, Lorenzo J, et al. (2009) Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population: A case-control study. International journal of cancer, 125,1851–1858.